Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2019

Open Access 01-12-2019 | Colorectal Cancer | Review

The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis

Author: Paul Laissue

Published in: Molecular Cancer | Issue 1/2019

Login to get access

Abstract

Colorectal cancer (CRC) is the third most commonly occurring cancer worldwide and the fourth most frequent cause of death having an oncological origin. It has been found that transcription factors (TF) dysregulation, leading to the significant expression modifications of genes, is a widely distributed phenomenon regarding human malignant neoplasias. These changes are key determinants regarding tumour’s behaviour as they contribute to cell differentiation/proliferation, migration and metastasis, as well as resistance to chemotherapeutic agents. The forkhead box (FOX) transcription factor family consists of an evolutionarily conserved group of transcriptional regulators engaged in numerous functions during development and adult life. Their dysfunction has been associated with human diseases. Several FOX gene subgroup transcriptional disturbances, affecting numerous complex molecular cascades, have been linked to a wide range of cancer types highlighting their potential usefulness as molecular biomarkers. At least 14 FOX subgroups have been related to CRC pathogenesis, thereby underlining their role for diagnosis, prognosis and treatment purposes.
This manuscript aims to provide, for the first time, a comprehensive review of FOX genes’ roles during CRC pathogenesis. The molecular and functional characteristics of most relevant FOX molecules (FOXO, FOXM1, FOXP3) have been described within the context of CRC biology, including their usefulness regarding diagnosis and prognosis. Potential CRC therapeutics (including genome-editing approaches) involving FOX regulation have also been included. Taken together, the information provided here should enable a better understanding of FOX genes’ function in CRC pathogenesis for basic science researchers and clinicians.
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi REM, Corcione F. Worldwide burden of colorectal cancer: a review. Updat Surg. 2016;68:7–11.CrossRef
3.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.PubMedCrossRef
4.
Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013;24:1207–22.PubMedPubMedCentralCrossRef
5.
6.
Gonzalez-Pons M, Cruz-Correa M. Colorectal cancer biomarkers: where are we now? Biomed Res Int. 2015;2015:1–14.CrossRef
7.
Simons CCJM, Hughes LAE, Smits KM, Khalid-de Bakker CA, de Bruïne AP, Carvalho B, et al. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann Oncol. 2013;24:2048–56.PubMedCrossRef
8.
9.
Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15:195–203.PubMedCrossRef
10.
Mahasneh A, Al-Shaheri F, Jamal E. Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: current updates. Exp Mol Pathol. 2017;102:475–83.PubMedCrossRef
11.
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.PubMedPubMedCentralCrossRef
12.
Roseweir AK, McMillan DC, Horgan PG, Edwards J. Colorectal cancer subtypes: translation to routine clinical pathology. Cancer Treat Rev. 2017;57:1–7.PubMedCrossRef
13.
Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:268.PubMedCrossRef
14.
15.
16.
17.
18.
Jacob F, Monod J. Genetic regulatory mechanisms in the synthesis of proteins. J Mol Biol. 1961;3:318–56.PubMedCrossRef
19.
Todeschini A-L, Georges A, Veitia RA. Transcription factors: specific DNA binding and specific gene regulation. Trends Genet. 2014;30:211–9.PubMedCrossRef
20.
Deplancke B, Alpern D, Gardeux V. The genetics of transcription factor DNA binding variation. Cell. 2016;166:538–54.PubMedCrossRef
21.
Boeva V. Analysis of genomic sequence motifs for deciphering transcription factor binding and transcriptional regulation in eukaryotic cells. Front Genet. 2016;7:24.PubMedPubMedCentralCrossRef
22.
Rosanova A, Colliva A, Osella M, Caselle M. Modelling the evolution of transcription factor binding preferences in complex eukaryotes. Sci Rep. 2017;7:7596.PubMedPubMedCentralCrossRef
23.
Liu F, Wang L, Perna F, Nimer SD. Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nat Rev Cancer. 2016;16:359–72.PubMedPubMedCentralCrossRef
24.
25.
26.
27.
28.
Spitz F, Furlong EEM. Transcription factors: from enhancer binding to developmental control. Nat Rev Genet. 2012;13:613–26.PubMedCrossRef
29.
30.
Altobelli G. Bioinformatics applied to gene transcription regulation. J Mol Endocrinol. 2012;49:R51–9.PubMedCrossRef
31.
Kilpinen H, Waszak SM, Gschwind AR, Raghav SK, Witwicki RM, Orioli A, et al. Coordinated effects of sequence variation on DNA binding, chromatin structure, and transcription. Science. 2013;342:744–7.PubMedPubMedCentralCrossRef
32.
Sandmann T, Jensen LJ, Jakobsen JS, Karzynski MM, Eichenlaub MP, Bork P, et al. A temporal map of transcription factor activity: mef2 directly regulates target genes at all stages of muscle development. Dev Cell. 2006;10:797–807.PubMedCrossRef
33.
Siggers T, Duyzend MH, Reddy J, Khan S, Bulyk ML. Non-DNA-binding cofactors enhance DNA-binding specificity of a transcriptional regulatory complex. Mol Syst Biol. 2014;7:555.CrossRef
34.
Slattery M, Riley T, Liu P, Abe N, Gomez-Alcala P, Dror I, et al. Cofactor binding evokes latent differences in DNA binding specificity between Hox proteins. Cell. 2011;147:1270–82.PubMedPubMedCentralCrossRef
35.
Cusanovich DA, Pavlovic B, Pritchard JK, Gilad Y. The functional consequences of variation in transcription factor binding. PLoS Genet. 2014;10:e1004226 Pilpel Y, editor.PubMedPubMedCentralCrossRef
36.
Myatt SS, Lam EW-F-F. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7:847–59.PubMedCrossRef
37.
38.
Benayoun BA, Caburet S, Veitia RA. Forkhead transcription factors: key players in health and disease. Trends Genet. 2011;27:224–32.PubMedCrossRef
39.
Lam EW-F, Brosens JJ, Gomes AR, Koo C-Y. Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer. 2013;13:482–95.PubMedCrossRef
40.
Katoh MM, Igarashi M, Fukuda H, Nakagama H, Katoh MM. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2013;328:198–206.PubMedCrossRef
41.
Lam EW-F, Gomes AR. Forkhead box transcription factors in cancer initiation, progression and chemotherapeutic drug response. Front Oncol. 2014;44:305.
42.
43.
Koo C-Y, Muir KW, Lam EW-F. FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta. 1819;2012:28–37.
44.
45.
Bullock MD, Bruce A, Sreekumar R, Curtis N, Cheung T, Reading I, et al. FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. Br J Cancer. 2013;109:387–94.PubMedPubMedCentralCrossRef
46.
Wang W, Li X, Lee M, Jun S, Aziz KE, Feng L, et al. FOXKs promote Wnt/β-catenin signaling by translocating DVL into the nucleus. Dev Cell. 2015;32:707–18.PubMedPubMedCentralCrossRef
47.
Liu K, Fan J, Wu J. Forkhead box protein J1 (FOXJ1) is overexpressed in colorectal cancer and promotes nuclear translocation of β-catenin in SW620 cells. Med Sci Monit. 2017;23:856–66.PubMedPubMedCentralCrossRef
48.
Bach D-H, Long NP, Luu T-T-T, Anh NH, Kwon SW, Lee SK. The dominant role of Forkhead box proteins in cancer. Int J Mol Sci. 2018;19.
49.
Mukherjee A, Hollern DP, Williams OG, Rayburn TS, Byrd WA, Yates C, et al. A review of FOXI3 regulation of development and possible roles in cancer progression and metastasis. Front Cell Dev Biol. 2018;6:69.
50.
Weigel D, Jürgens G, Küttner F, Seifert E, Jäckle H. The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell. 1989;57:645–58.PubMedCrossRef
51.
Weigel D, Jäckle H. The fork head domain: a novel DNA binding motif of eukaryotic transcription factors? Cell. 1990;63:455–6.PubMedCrossRef
52.
Katoh M, Katoh M. Human FOX gene family (review). Int J Oncol. 2004;25:1495–500.PubMed
53.
Jackson BC, Carpenter C, Nebert DW, Vasiliou V. Update of human and mouse forkhead box (FOX) gene families. Hum Genomics. 2010;4:345–52.PubMedPubMedCentral
54.
Shimeld SM, Degnan B, Luke GN. Evolutionary genomics of the Fox genes: origin of gene families and the ancestry of gene clusters. Genomics. 2010;95:256–60.PubMedCrossRef
55.
Lai E, Clark KL, Burley SK, Darnell JE. Hepatocyte nuclear factor 3/fork head or “winged helix” proteins: a family of transcription factors of diverse biologic function. Proc Natl Acad Sci U S A. 1993;90:10421–3.PubMedPubMedCentralCrossRef
56.
Overdier DG, Porcella A, Costa RH. The DNA-binding specificity of the hepatocyte nuclear factor 3/forkhead domain is influenced by amino-acid residues adjacent to the recognition helix. Mol Cell Biol. 1994;14:2755–66.PubMedPubMedCentralCrossRef
57.
Nakagawa S, Gisselbrecht SS, Rogers JM, Hartl DL, Bulyk ML. DNA-binding specificity changes in the evolution of forkhead transcription factors. Proc Natl Acad Sci. 2013;110:12349–54.PubMedCrossRefPubMedCentral
58.
Marsden I, Jin C, Liao X. Structural changes in the region directly adjacent to the DNA-binding helix highlight a possible mechanism to explain the observed changes in the sequence-specific binding of winged helix proteins. J Mol Biol. 1998;278:293–9.PubMedCrossRef
59.
Clark KL, Halay ED, Lai E, Burley SK. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature. 1993;364:412–20.PubMedCrossRef
60.
Obsil T, Obsilova V. Structure/function relationships underlying regulation of FOXO transcription factors. Oncogene. 2008;27:2263–75.PubMedCrossRef
61.
Cirillo LA, Zaret KS. Specific interactions of the wing domains of FOXA1 transcription factor with DNA. J Mol Biol. 2007;366:720–4.PubMedCrossRef
62.
Caburet S, Demarez A, Moumné L, Fellous M, De Baere E, Veitia RA. A recurrent polyalanine expansion in the transcription factor FOXL2 induces extensive nuclear and cytoplasmic protein aggregation. J Med Genet. 2004;41:932–6.PubMedPubMedCentralCrossRef
63.
Moumne L, Dipietromaria A, Batista F, Kocer A, Fellous M, Pailhoux E, et al. Differential aggregation and functional impairment induced by polyalanine expansions in FOXL2, a transcription factor involved in cranio-facial and ovarian development. Hum Mol Genet. 2007;17:1010–9.PubMedCrossRef
64.
Zhao Y, Ma H, Wang Y, Gao H, Xi C, Hua T, et al. Association between FOXP2 gene and speech sound disorder in Chinese population. Psychiatry Clin Neurosci. 2010;64:565–73.PubMedCrossRef
65.
Berman H, Henrick K, Nakamura H. Announcing the worldwide protein data bank. Nat Struct Mol Biol. 2003;10:980.CrossRef
66.
Wang Y, Zhou Y, Graves DT. FOXO transcription factors: their clinical significance and regulation. Biomed Res Int. 2014;2014:1–13.
67.
Brent MM, Anand R, Marmorstein R. Structural basis for DNA recognition by FoxO1 and its regulation by posttranslational modification. Structure. 2008;16:1407–16.PubMedPubMedCentralCrossRef
68.
Hou T, Li Z, Zhao Y, Zhu W-G. Mechanisms controlling the anti-neoplastic functions of FoxO proteins. Semin Cancer Biol. 2018;50:101–14.PubMedCrossRef
69.
Eijkelenboom A, Burgering BMT. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol. 2013;14:83–97.CrossRefPubMed
70.
Martins R, Lithgow GJ, Link W. Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. Aging Cell. 2016;15:196–207.PubMedCrossRef
71.
72.
73.
74.
González-Quiroz M, Urra H, Limia CM, Hetz C. Homeostatic interplay between FoxO proteins and ER proteostasis in cancer and other diseases. Semin Cancer Biol. 2018;50:42–52.PubMedCrossRef
75.
76.
Hornsveld M, Dansen TB, Derksen PW, Burgering BMT. Re-evaluating the role of FOXOs in cancer. Semin Cancer Biol. 2018;50:90–100.PubMedCrossRef
77.
Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol. 2001;21:952–65.PubMedPubMedCentralCrossRef
78.
van der Heide LP, Hoekman MFM, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J. 2004;380:297–309.CrossRef
79.
80.
Coomans de Brachène A, Demoulin J-B. FOXO transcription factors in cancer development and therapy. Cell Mol Life Sci. 2016;73:1159–72.PubMedCrossRef
81.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857–68.PubMedCrossRef
82.
Hu MC-T, Lee D-F, Xia W, Golfman LS, Ou-Yang F, Yang J-Y, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 2004;117:225–37.PubMedCrossRef
83.
Yang J-Y, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10:138–48.PubMedPubMedCentralCrossRef
84.
85.
86.
Qi W, Weber CR, Wasland K, Savkovic SD. Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. BMC Cancer. 2011;11:219.PubMedPubMedCentralCrossRef
87.
Qi W, Weber CR, Wasland K, Roy H, Wali R, Joshi S, et al. Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells. Am J Physiol Liver Physiol. 2011;300:G264–72.
88.
Luo H, Yang Y, Duan J, Wu P, Jiang Q, Xu C. PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells. Cell Death Dis. 2013;4:e481.PubMedPubMedCentralCrossRef
89.
Qi W, Fitchev PS, Cornwell ML, Greenberg J, Cabe M, Weber CR, et al. FOXO3 growth inhibition of colonic cells is dependent on intraepithelial lipid droplet density. J Biol Chem. 2013;288:16274–81.PubMedPubMedCentralCrossRef
90.
Shoeb M, Ramana KV, Srivastava SK. Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors. Free Radic Biol Med. 2013;63:280–90.PubMedPubMedCentralCrossRef
91.
Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, et al. miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res. 2013;73:6435–47.PubMedCrossRef
92.
Germani A, Matrone A, Grossi V, Peserico A, Sanese P, Liuzzi M, et al. Targeted therapy against chemoresistant colorectal cancers: inhibition of p38α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Lett. 2014;344:110–8.PubMedCrossRef
93.
Cui Y-M, Jiang D, Zhang S-H, Wu P, Ye Y-P, Chen C-M, et al. FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways. Cancer Lett. 2014;353:87–94.PubMedCrossRef
94.
Gao F, Wang W. MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a. Mol Med Rep. 2015;11:1200–6.PubMedCrossRef
95.
Qazi AK, Hussain A, Khan S, Aga MA, Behl A, Ali S, et al. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer. Cancer Lett. 2015;359:47–56.PubMedCrossRef
96.
Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem–like cells in an Akt/Foxo3a/TRAIL–dependent manner. Cancer Res. 2015;75:1423–32.PubMedPubMedCentralCrossRef
97.
Sarkar M, Khare V, Guturi KKN, Das N, Ghosh MK. The DEAD box protein p68: a crucial regulator of AKT/FOXO3a signaling axis in oncogenesis. Oncogene. 2015;34:5843–56.PubMedCrossRef
98.
Kops GJPL, Medema RH, Glassford J, Essers MAG, Dijkers PF, Coffer PJ, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol. 2002;22:2025–36.PubMedPubMedCentralCrossRef
99.
Penrose H, Heller S, Cable C, Makboul R, Chadalawada G, Chen Y, et al. Epidermal growth factor receptor mediated proliferation depends on increased lipid droplet density regulated via a negative regulatory loop with FOXO3/Sirtuin6. Biochem Biophys Res Commun. 2016;469:370–6.PubMedCrossRef
100.
Fu Q, Du Y, Yang C, Zhang D, Zhang N, Liu X, et al. An oncogenic role of miR-592 in tumorigenesis of human colorectal cancer by targeting Forkhead Box O3A (FoxO3A). Expert Opin Ther Targets. 2016;20:771–82.PubMedCrossRef
101.
Fluckiger A, Dumont A, Derangère V, Rébé C, de Rosny C, Causse S, et al. Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNFα. Oncogene. 2016;35:4611–22.PubMedCrossRef
102.
Park S-Y, Bae Y-S. Inactivation of the FoxO3a transcription factor is associated with the production of reactive oxygen species during protein kinase CK2 downregulation-mediated senescence in human colon cancer and breast cancer cells. Biochem Biophys Res Commun. 2016;478:18–24.PubMedCrossRef
103.
Marzi L, Combes E, Vié N, Ayrolles-Torro A, Tosi D, Desigaud D, et al. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. Br J Cancer. 2016;115:1223–33.PubMedPubMedCentralCrossRef
104.
Song K-H, Woo SR, Chung J-Y, Lee H-J, Oh SJ, Hong S-O, et al. REP1 inhibits FOXO3-mediated apoptosis to promote cancer cell survival. Cell Death Dis. 2017;8:e2536.PubMedPubMedCentralCrossRef
105.
Karki R, Malireddi RKS, Zhu Q, Kanneganti T-D. NLRC3 regulates cellular proliferation and apoptosis to attenuate the development of colorectal cancer. Cell Cycle. 2017;16:1243–51.PubMedPubMedCentralCrossRef
106.
Pan S, Deng Y, Fu J, Zhang Y, Zhang Z, Ru X, et al. Decreased expression of ARHGAP15 promotes the development of colorectal cancer through PTEN/AKT/FOXO1 axis. Cell Death Dis. 2018;9:673.PubMedPubMedCentralCrossRef
107.
Yang Z, Liu S, Zhu M, Zhang H, Wang J, Xu Q, et al. PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway. Sci Rep. 2016;6:22090.PubMedPubMedCentralCrossRef
108.
Xie J, Xiang D-B, Wang H, Zhao C, Chen J, Xiong F, et al. Inhibition of Tcf-4 induces apoptosis and enhances chemosensitivity of colon cancer cells. PLoS One. 2012;7:e45617.PubMedPubMedCentralCrossRef
109.
Fernández de Mattos S, Villalonga P, Clardy J, Lam EW-F. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther. 2008;7:3237–46.PubMedCrossRef
110.
Dehner M, Hadjihannas M, Weiske J, Huber O, Behrens J. Wnt signaling inhibits Forkhead box O3a-induced transcription and apoptosis through up-regulation of serum- and glucocorticoid-inducible kinase 1. J Biol Chem. 2008;283:19201–10.PubMedCrossRef
111.
Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, et al. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci. 2010;107:2598–603.PubMedCrossRefPubMedCentral
112.
Sun Y, Zhao S, Tian H, Xie X, Xiao F, Li K, et al. Depletion of PI3K p85alpha induces cell cycle arrest and apoptosis in colorectal cancer cells. Oncol Rep. 2009;22:1435–41.PubMedCrossRef
113.
Nasir O, Wang K, Föller M, Gu S, Bhandaru M, Ackermann TF, et al. Relative resistance of SGK1 knockout mice against chemical carcinogenesis. IUBMB Life. 2009;61:768–76.PubMedCrossRef
114.
Wu L, Li H, Jia CY, Cheng W, Yu M, Peng M, et al. MicroRNA-223 regulates FOXO1 expression and cell proliferation. FEBS Lett. 2012;586:1038–43.PubMedCrossRef
115.
Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med. 2012;18:892–901.CrossRefPubMed
116.
117.
Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329–41.PubMedCrossRef
118.
Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta. 1813;2011:1938–45.
119.
Karki R, Man SM, Malireddi RKS, Kesavardhana S, Zhu Q, Burton AR, et al. NLRC3 is an inhibitory sensor of PI3K–mTOR pathways in cancer. Nature. 2016;540:583–7.CrossRefPubMedPubMedCentral
120.
Yao G, Zhang Y, Chen P, Ren X. MicroRNA-544 promotes colorectal cancer progression by targeting forkhead box O1. Oncol Lett. 2017;15:991-7.
121.
Korver W, Roose J, Heinen K, Weghuis DO, de Bruijn D, van Kessel AG, et al. The HumanTRIDENT/HFH-11/FKHL16Gene: structure, localization, and promoter characterization. Genomics. 1997;46:435–42.PubMedCrossRef
122.
Yao KM, Sha M, Lu Z, Wong GG. Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. J Biol Chem. 1997;272:19827–36.PubMedCrossRef
123.
Ma RYM. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci. 2005;118:795–806.PubMedCrossRef
124.
Chu X-Y, Zhu Z-M, Chen L-B, Wang J-H, Su Q-S, Yang J-R, et al. FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem. 2012;114:755–62.PubMedCrossRef
125.
Li D, Wei P, Peng Z, Huang C, Tang H, Jia Z, et al. The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis. Clin Cancer Res. 2013;19:62–72.PubMedCrossRef
126.
Zhang HG, Xu XW, Shi XP, Han BW, Li ZH, Ren WH, et al. Overexpression of forkhead box protein M1 (FOXM1) plays a critical role in colorectal cancer. Clin Transl Oncol. 2016;18:527–32.PubMedCrossRef
127.
Zhang H, Zhong H, Li L, Ji W, Zhang X. Overexpressed transcription factor FOXM1 contributes to the progression of colorectal cancer. Mol Med Rep. 2016;13:2696–700.PubMedCrossRef
128.
Zhang J, Zhang K, Zhou L, Wu W, Jiang T, Cao J, et al. Expression and potential correlation among Forkhead box protein M1, Caveolin-1 and E-cadherin in colorectal cancer. Oncol Lett. 2016;12:2381–8.PubMedPubMedCentralCrossRef
129.
Douard R, Moutereau S, Pernet P, Chimingqi M, Allory Y, Manivet P, et al. Sonic Hedgehog-dependent proliferation in a series of patients with colorectal cancer. Surgery. 2006;139:665–70.PubMedCrossRef
130.
Wang D, Hu G, Du Y, Zhang C, Lu Q, Lv N, et al. Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells. J Exp Clin Cancer Res. 2017;36:23.PubMedPubMedCentralCrossRef
131.
Zhang C, Wang Y, Feng Y, Zhang Y, Ji B, Wang S, et al. Gli1 promotes colorectal cancer metastasis in a Foxm1-dependent manner by activating EMT and PI3K-AKT signaling. Oncotarget. 2016;7:86134-47.
132.
Zhang R, Wu J, Ferrandon S, Glowacki KJ, Houghton JA. Targeting GLI by GANT61 involves mechanisms dependent on inhibition of both transcription and DNA licensing. Oncotarget. 2016;7:80190-207.
133.
Zheng Y, Guo J, Zhou J, Lu J, Chen Q, Zhang C, et al. FoxM1 transactivates PTTG1 and promotes colorectal cancer cell migration and invasion. BMC Med Genet. 2015;8:49.
134.
Luo X, Yao J, Nie P, Yang Z, Feng H, Chen P, et al. FOXM1 promotes invasion and migration of colorectal cancer cells partially dependent on HSPA5 transactivation. Oncotarget. 2016;7:26480–95.PubMedPubMedCentral
135.
Jiang Z, Xu Y, Cai S. Down-regulated GAS1 expression correlates with recurrence in stage II and III colorectal cancer. Hum Pathol. 2011;42:361–8.PubMedCrossRef
136.
Li Q, Qin Y, Wei P, Lian P, Li Y, Xu Y, et al. Gas1 inhibits metastatic and metabolic phenotypes in colorectal carcinoma. Mol Cancer Res. 2016;14:830–40.PubMedCrossRef
137.
Song I-S, Jeong YJ, Jeong SH, Heo HJ, Kim HK, Bae KB, et al. FOXM1-induced PRX3 regulates stemness and survival of colon cancer cells via maintenance of mitochondrial function. Gastroenterology. 2015;149:1006–1016.e9.PubMedCrossRef
138.
139.
Zhang X, Zhang L, Du Y, Zheng H, Zhang P, Sun Y, et al. A novel FOXM1 isoform, FOXM1D, promotes epithelial–mesenchymal transition and metastasis through ROCKs activation in colorectal cancer. Oncogene. 2017;36:807–19.PubMedCrossRef
140.
Wan L-Y, Deng J, Xiang X-J, Zhang L, Yu F, Chen J, et al. miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun. 2015;457:125–32.PubMedCrossRef
141.
Xu K, Liu X, Mao X, Xue L, Wang R, Chen L, et al. MicroRNA-149 suppresses colorectal Cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem. 2015;35:499–515.PubMedCrossRef
142.
Liu X, Xie T, Mao X, Xue L, Chu X, Chen L. MicroRNA-149 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem. 2016;39:617–29.PubMedCrossRef
143.
Vishnubalaji R, Hamam R, Yue S, Al-Obeed O, Kassem M, Liu F-F, et al. MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1. Oncotarget. 2016;7:35789-802.
144.
Weng W, Okugawa Y, Toden S, Toiyama Y, Kusunoki M, Goel A. FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor-suppressive miR-342 in human colorectal cancer. Clin Cancer Res. 2016;22:4947–57.PubMedPubMedCentralCrossRef
145.
Xu X-S, Miao R-C, Wan Y, Zhang L-Q, Qu K, Liu C. FoxM1 as a novel therapeutic target for cancer drug therapy. Asian Pac J Cancer Prev. 2015;16:23–9.PubMedCrossRef
146.
147.
Russell WL, Russell LB, Gower JS. Exceptional inheritance of a sex-linked gene in the mouse explained on the basis that the X/O sex-chromosome constitution is female. Proc Natl Acad Sci U S A. 1959;45:554–60.PubMedPubMedCentralCrossRef
148.
149.
150.
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.PubMedCrossRef
151.
Khattri R, Cox T, Yasayko S-A, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4:337–42.PubMedCrossRef
152.
Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol. 2007;7:305–10.PubMedCrossRef
153.
Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001;27:68–73.PubMedCrossRef
154.
Triulzi T, Tagliabue E, Balsari A, Casalini P. FOXP3 expression in tumor cells and implications for cancer progression. J Cell Physiol. 2013;228:30–5.PubMedCrossRef
155.
Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. 2000;106:R75–81.PubMedPubMedCentralCrossRef
156.
Bacchetta R, Barzaghi F, Roncarolo M-G. From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. Ann N Y Acad Sci. 2018;1417:5–22.PubMedCrossRef
157.
Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27:18–20.PubMedCrossRef
158.
Lopes JE, Torgerson TR, Schubert LA, Anover SD, Ocheltree EL, Ochs HD, et al. Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor. J Immunol. 2006;177:3133–42.PubMedCrossRef
159.
160.
Mercer F, Unutmaz D. The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer. Adv Exp Med Biol. 2009;665:47–59.PubMedPubMedCentralCrossRef
161.
Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli F. Human FOXP3 and cancer. Oncogene. 2010;29:4121–9.PubMedCrossRef
162.
Szylberg Ł, Karbownik D, Marszałek A. The role of FOXP3 in human cancers. Anticancer Res. 2016;36:3789–94.PubMed
163.
164.
165.
Ward-Hartstonge KA, Kemp RA. Regulatory T-cell heterogeneity and the cancer immune response. Clin Transl Immunol. 2017;6:e154.CrossRef
166.
Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007;129:1275–86.PubMedPubMedCentralCrossRef
167.
168.
169.
170.
171.
Xu P, Fan W, Zhang Z, Wang J, Wang P, Li Y, et al. The clinicopathological and prognostic implications of FoxP3+ regulatory T cells in patients with colorectal cancer: a meta-analysis. Front Physiol. 2017;8:950.
172.
Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009;137:1270–9.PubMedCrossRef
173.
Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306.CrossRefPubMed
174.
Suzuki H, Onishi H, Morisaki T, Tanaka M, Katano M. Intratumoral FOXP3+VEGFR2+ regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer. Clin Immunol. 2013;146:26–33.PubMedCrossRef
175.
Huang Y, Liao H, Zhang Y, Yuan R, Wang F, Gao Y, et al. Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis. PLoS One. 2014;9:e94376 Seno M, editor.PubMedPubMedCentralCrossRef
176.
Shang B, Liu Y, Jiang S, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179.PubMedPubMedCentralCrossRef
177.
Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One. 2012;7:e42274.PubMedPubMedCentralCrossRef
178.
Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, et al. Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22:679–84.PubMedCrossRef
179.
Ouyang W, Beckett O, Ma Q, Paik J, DePinho RA, Li MO. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol. 2010;11:618–27.PubMedCrossRef
180.
181.
182.
Zheng Y, Josefowicz SZ, Kas A, Chu T-T, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007;445:936–40.PubMedCrossRef
183.
Rudra D, DeRoos P, Chaudhry A, Niec RE, Arvey A, Samstein RM, et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol. 2012;13:1010–9.PubMedPubMedCentralCrossRef
184.
Hori S. The Foxp3 interactome: a network perspective of T(reg) cells. Nat Immunol. 2012;13:943–5.PubMedCrossRef
185.
Cui Y-M, Jiao H-L, Ye Y-P, Chen C-M, Wang J-X, Tang N, et al. FOXC2 promotes colorectal cancer metastasis by directly targeting MET. Oncogene. 2015;34:4379–90.PubMedCrossRef
186.
Li Q, Wu J, Wei P, Xu Y, Zhuo C, Wang Y, et al. Overexpression of forkhead Box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial-mesenchymal transition. Am J Cancer Res. 2015;5:2022–34.PubMedPubMedCentral
187.
Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. Forkhead box C1 promotes colorectal cancer metastasis through transactivating ITGA7 and FGFR4 expression. Oncogene. 2018;37:5477–91.PubMedCrossRef
188.
Qiao Y, Jiang X, Lee ST, Karuturi RKM, Hooi SC, Yu Q. FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Cancer Res. 2011;71:3076–86.PubMedCrossRef
189.
Li Y, Zhang Y, Yao Z, Li S, Yin Z, Xu M. Forkhead box Q1: a key player in the pathogenesis of tumors (review). Int J Oncol. 2016;49:51–8.PubMedCrossRef
190.
Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, et al. FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res. 2010;70:2053–63.PubMedCrossRef
191.
Christensen J, Bentz S, Sengstag T, Shastri VP, Anderle P. FOXQ1, a novel target of the Wnt pathway and a new marker for activation of Wnt signaling in solid tumors. PLoS One. 2013;8:e60051 Samant R, editor.PubMedPubMedCentralCrossRef
192.
Peng X, Luo Z, Kang Q, Deng D, Wang Q, Peng H, et al. FOXQ1 mediates the crosstalk between TGF-β and Wnt signaling pathways in the progression of colorectal cancer. Cancer Biol Ther. 2015;16:1099–109.PubMedPubMedCentralCrossRef
193.
Lu S-Q, Qiu Y, Dai W-J, Zhang X-Y. FOXR2 promotes the proliferation, invasion, and epithelial-mesenchymal transition in human colorectal Cancer cells. Oncol Res. 2017;25:681–9.PubMedCrossRefPubMedCentral
194.
Quintero-Ronderos P, Laissue P. The multisystemic functions of FOXD1 in development and disease. J Mol Med. 2018;96:725–39.PubMedCrossRef
195.
Han T, Lin J, Wang Y, Fan Q, Sun H, Tao Y, et al. Forkhead box D1 promotes proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer. Biomed Pharmacother. 2018;103:1369–75.PubMedCrossRef
196.
Huang X, Xiang L, Li Y, Zhao Y, Zhu H, Xiao Y, et al. Snail/FOXK1/Cyr61 signaling axis regulates the epithelial–mesenchymal transition and metastasis in colorectal cancer. Cell Physiol Biochem. 2018;47:590–603.PubMedCrossRef
197.
Lo P-K, Lee JS, Sukumar S. The p53–p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function. Cell Signal. 2012;24:316–24.PubMedCrossRef
198.
Ma W, Jiang J, Li M, Wang H, Zhang H, He X, et al. The clinical significance of forkhead box protein A1 and its role in colorectal cancer. Mol Med Rep. 2016;14:2625–31.PubMedPubMedCentralCrossRef
199.
He GY, Hu JL, Zhou L, Zhu XH, Xin SN, Zhang D, et al. The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer. Br J Cancer. 2016;115:1367–78.PubMedPubMedCentralCrossRef
200.
Wu M, Wang J, Tang W, Zhan X, Li Y, Peng Y, et al. FOXK1 interaction with FHL2 promotes proliferation, invasion and metastasis in colorectal cancer. Oncogene. 2016;5:e271.CrossRef
201.
Wu Y, Peng Y, Wu M, Zhang W, Zhang M, Xie R, et al. Oncogene FOXK1 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition. Oncotarget. 2016;7:51150-62.
202.
Wu Y, Xie R, Liu X, Wang J, Peng Y, Tang W, et al. Knockdown of FOXK1 alone or in combination with apoptosis-inducing 5-FU inhibits cell growth in colorectal cancer. Oncol Rep. 2016;36:2151–9.PubMedCrossRef
203.
Li K, Guo Q, Yang J, Chen H, Hu K, Zhao J, et al. FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway. Oncotarget. 2017;8:5048-56.
204.
Qian Y, Xia S, Feng Z. Sox9 mediated transcriptional activation of FOXK2 is critical for colorectal cancer cells proliferation. Biochem Biophys Res Commun. 2017;483:475–81.PubMedCrossRef
205.
Nik AM, Reyahi A, Pontén F, Carlsson P. Foxf2 in intestinal fibroblasts reduces numbers of Lgr5+ stem cells and adenoma formation by inhibiting Wnt signaling. Gastroenterology. 2013;144:1001–11.PubMedCrossRef
206.
Melotte V, Yi JM, Lentjes MHFM, Smits KM, Van Neste L, Niessen HEC, et al. Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood. Cancer Prev Res. 2015;8:157–64.CrossRef
207.
Sugimachi K, Matsumura T, Shimamura T, Hirata H, Uchi R, Ueda M, et al. Aberrant methylation of FOXE1 contributes to a poor prognosis for patients with colorectal cancer. Ann Surg Oncol. 2016;23:3948–55.PubMedCrossRef
208.
Ma W, Yu Q, Jiang J, Du X, Huang L, Zhao L, et al. miR-517a is an independent prognostic marker and contributes to cell migration and invasion in human colorectal cancer. Oncol Lett. 2016;11:2583–9.PubMedPubMedCentralCrossRef
209.
Chen W, Tong K, Yu J. MicroRNA-130a is upregulated in colorectal cancer and promotes cell growth and motility by directly targeting forkhead box F2. Mol Med Rep. 2017;16:5241–8.PubMedPubMedCentralCrossRef
210.
Dai Y, Wang M, Wu H, Xiao M, Liu H, Zhang D. Loss of FOXN3 in colon cancer activates beta-catenin/TCF signaling and promotes the growth and migration of cancer cells. Oncotarget. 2017;8:9783-93.
211.
212.
213.
Gayvert KM, Dardenne E, Cheung C, Boland MR, Lorberbaum T, Wanjala J, et al. A computational drug repositioning approach for targeting oncogenic transcription factors. Cell Rep. 2016;15:2348–56.PubMedPubMedCentralCrossRef
214.
Lambert M, Jambon S, Depauw S, David-Cordonnier M-H. Targeting transcription factors for cancer treatment. Molecules. 2018;23:1479.PubMedCentralCrossRef
215.
Liu X, Cai X, Hu B, Mei Z, Zhang D, Ouyang G, et al. Forkhead transcription factor 3a (FOXO3a) modulates hypoxia signaling via up-regulation of the von Hippel-Lindau gene (VHL). J Biol Chem. 2016;291:25692–705.PubMedPubMedCentralCrossRef
216.
Okada M, Kanamori M, Someya K, Nakatsukasa H, Yoshimura A. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells. Epigenetics Chromatin. 2017;10:24.PubMedPubMedCentralCrossRef
Metadata
Title
The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis
Author
Paul Laissue
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2019
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-019-0938-x

Other articles of this Issue 1/2019

Molecular Cancer 1/2019 Go to the issue

Research

N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway

Research

METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer

Research

MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2/cofilin pathway in NSCLC

Research

Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression

Research

Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression

Review

TAMing pancreatic cancer: combat with a double edged sword
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits